Msa Safety Inc. logo

Msa Safety Inc. (MSA)

Market Closed
16 Oct, 08:00 PM
NYSE NYSE
$
179. 05
-2.74
-1.5072%
$
6.98B Market Cap
125.37 P/E Ratio
1.88% Div Yield
215,400 Volume
7.73 Eps
$ 181.79
Previous Close
Add Transaction
Day Range
177.8 184.64
Year Range
151.11 208.92
Want to track MSA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
MSA Safety Incorporated (MSA) Q3 2025 Earnings Call Transcript

MSA Safety Incorporated (MSA) Q3 2025 Earnings Call Transcript

MSA Safety Incorporated ( MSA ) Q3 2025 Earnings Call October 29, 2025 10:00 AM EDT Company Participants Lawrence De Maria - Executive Director of Investor Relations Steven Blanco - President, CEO & Director Julie Beck - SVP, CFO & Treasurer Conference Call Participants Robert Mason - Robert W. Baird & Co. Incorporated, Research Division Ross Sparenblek - William Blair & Company L.L.C.

Seekingalpha | 11 months ago
MSA Safety (MSA) Beats Q3 Earnings and Revenue Estimates

MSA Safety (MSA) Beats Q3 Earnings and Revenue Estimates

MSA Safety (MSA) came out with quarterly earnings of $1.94 per share, beating the Zacks Consensus Estimate of $1.9 per share. This compares to earnings of $1.83 per share a year ago.

Zacks | 11 months ago
Tiziana Life Sciences doses first MSA patient in new trial – ICYMI

Tiziana Life Sciences doses first MSA patient in new trial – ICYMI

Tiziana Life Sciences Ltd (NASDAQ:TLSA) CEO Ivor Elrifi talked with Proactive about the company's latest milestone: dosing the first patient in its Phase 2a clinical trial targeting multiple system atrophy (MSA), a rare and fatal neurodegenerative condition with no approved treatment. Elrifi explained the trial involves the company's investigational monoclonal antibody, Foralumab, which is administered intranasally and aims to reduce neuroinflammation.

Proactiveinvestors | 1 year ago
Tiziana Life Sciences doses first patient in Phase 2a MSA trial

Tiziana Life Sciences doses first patient in Phase 2a MSA trial

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has enrolled and dosed the first participant in its Phase 2a clinical trial evaluating intranasal foralumab in patients with Multiple System Atrophy (MSA).   The trial is being conducted at Brigham and Women's Hospital in Boston, Massachusetts.

Proactiveinvestors | 1 year ago
MSA Safety Incorporated (MSA) Q2 2025 Earnings Conference Call Transcript

MSA Safety Incorporated (MSA) Q2 2025 Earnings Conference Call Transcript

MSA Safety Incorporated (NYSE:MSA ) Q2 2025 Earnings Call August 5, 2025 10:00 AM ET Company Participants Elyse L. Brody - Interim Chief Financial Officer Lawrence Tighe De Maria - Executive Director of Investor Relations Steven C.

Seekingalpha | 1 year ago
MSA Safety (MSA) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

MSA Safety (MSA) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for MSA Safety (MSA) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks | 1 year ago
MSA Safety (MSA) Q2 Earnings and Revenues Top Estimates

MSA Safety (MSA) Q2 Earnings and Revenues Top Estimates

MSA Safety (MSA) came out with quarterly earnings of $1.93 per share, beating the Zacks Consensus Estimate of $1.76 per share. This compares to earnings of $2.01 per share a year ago.

Zacks | 1 year ago
Analysts Estimate MSA Safety (MSA) to Report a Decline in Earnings: What to Look Out for

Analysts Estimate MSA Safety (MSA) to Report a Decline in Earnings: What to Look Out for

MSA Safety (MSA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 1 year ago
MSA Safety Incorporated (MSA) Q1 2025 Earnings Call Transcript

MSA Safety Incorporated (MSA) Q1 2025 Earnings Call Transcript

MSA Safety Incorporated (NYSE:MSA ) Q1 2025 Earnings Conference Call April 30, 2025 10:00 AM ET Company Participants Larry De Maria - Executive Director of IR Steven Blanco - President and CEO Elyse Brody - Interim CFO Conference Call Participants Rob Mason - Baird Ross Sparenblek - William Blair Jeff Van Sinderen - B. Riley FBR Mike Shlisky - D.A.

Seekingalpha | 1 year ago
MSA Safety (MSA) Beats Q1 Earnings and Revenue Estimates

MSA Safety (MSA) Beats Q1 Earnings and Revenue Estimates

MSA Safety (MSA) came out with quarterly earnings of $1.68 per share, beating the Zacks Consensus Estimate of $1.59 per share. This compares to earnings of $1.61 per share a year ago.

Zacks | 1 year ago
All You Need to Know About MSA Safety (MSA) Rating Upgrade to Buy

All You Need to Know About MSA Safety (MSA) Rating Upgrade to Buy

MSA Safety (MSA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks | 1 year ago
MSA Safety (MSA) Surges 8.1%: Is This an Indication of Further Gains?

MSA Safety (MSA) Surges 8.1%: Is This an Indication of Further Gains?

MSA Safety (MSA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks | 1 year ago
Loading...
Load More